Subjects in these studies had compensated liver disease, detectable HCV-RNA, and liver histopathology consistent with chronic
hepatitis C. In all three studies, INCIVEK was administered at a
dosage of 750 mg every 8 hours; the peginterferon alfa-2a (Peg-IFN-alfa-2a) dose was 180 μg/week, and the ribavirin (RBV) dose was 1000 mg/day (subjects weighing less than 75 kg) or 1200 mg/day (subjects weighing greater than or equal to 75 kg).